\section*{β-Adrenergic and Atrial Natriuretic Peptide Interactions on Human Cardiovascular and Metabolic Regulation}

Andreas L. Birkenfeld, Michael Boschmann, Cedric Moro, Frauke Adams, Karsten Heusser, Jens Tank, André Diedrich, Christoph Schroeder, Gabi Franke, Michel Berlan, Friedrich C. Luft, Max Lafontan, and Jens Jordan

Franz-Volhard Clinical Research Center (A.L.B., M.Bo., F.A., K.H., J.T., C.S., G.F., F.C.L., J.J.), Charité Campus Buch and HELIOS Klinikum, 13125 Berlin, Germany; Institut National de la Santé et de la Recherche Médicale Unit 586 (C.M., M.Be., M.L.), Institut Louis Bugnard, Université Paul Sabatier, Hôpital Rangueil, 31403 Toulouse, France; and Autonomic Dysfunction Center (A.D.), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical School, Nashville, Tennessee 37232

Context: Atrial natriuretic peptide (ANP) has well-known cardiovascular effects and modifies lipid and carbohydrate metabolism in humans.

Objective: The objective of the study was to determine the metabolic and cardiovascular interaction of β-adrenergic receptors and ANP.

Design: This was a crossover study, conducted 2004–2005.

Setting: The study was conducted at an academic clinical research center.

Patients: Patients included 10 healthy young male subjects (body mass index 24 ± 1 kg/m²).

Intervention: We infused iv incremental ANP doses (6.25, 12.5, and 25 mg/kg/min) with and without propranolol (0.20 mg/kg in divided doses followed by 0.033 mg/kg/h infusion). Metabolism was monitored through venous blood sampling, im, and sc microdialysis and indirect calorimetry. Cardiovascular changes were monitored by continuous electrocardiogram and beat-by-beat blood pressure recordings.

**Main Outcome Measures:** Venous nonesterified fatty acid, glycerol, glucose, and insulin; and microdialysate glucose, glycerol, lactate, and pyruvate were measured.

**Results:** ANP increased heart rate dose dependently. β-Adrenergic receptor blockade abolished the response. ANP elicited a dose-dependent increase in serum nonesterified fatty acid and glycerol concentrations. The response was not suppressed with propranolol. Venous glucose and insulin concentrations increased with ANP, both without or with propranolol. ANP induced lipid mobilization in sc adipose tissue. In skeletal muscle, microdialysate lactate increased, whereas the lactate to pyruvate ratio decreased, both with and without propranolol. Higher ANP doses increased lipid oxidation, whereas energy expenditure remained unchanged. Propranolol tended to attenuate the increase in lipid oxidation.

**Conclusions:** Selected cardiovascular ANP effects are at least partly mediated by β-adrenergic receptor stimulation. ANP-induced changes in lipid mobilization and glycolysis are mediated by another mechanism, presumably stimulation of natriuretic peptide receptors, whereas substrate oxidation might be modulated through adrenergic mechanisms. (J Clin Endocrinol Metab 91: 5069–5075, 2006)
in particular adipose tissue lipolysis, are secondary to β-adrenergic receptor stimulation.

**Subjects and Methods**

**Subjects**

We studied 10 healthy men (age 32 ± 2 yr, body mass index 24 ± 1 kg/m², waist to hip ratio 0.82 ± 0.05). They received no medications. Human sc adipose tissue for *in vitro* experiments was obtained from six moderately overweight women undergoing plastic surgery (34 ± 1 yr, body mass index 26 ± 1 kg/m²). Written informed consent was obtained before study entry. The institutional review board approved all studies including sampling of adipocytes from surgical specimen.

**Protocol**

Subjects abstained from smoking, ingesting alcohol, drinking caffeine-containing beverages, and exercising vigorously 48 h before the experiments. We conducted all experiments in the morning after an overnight fast. Probands remained supine throughout the experiment. ANP was infused on 2 separate days, either with or without the nonselective β-adrenergic receptor blocker propranolol in a crossover fashion. The washout phase between experiments was at least 7 d. After a resting phase of 30 min, we obtained baseline indirect calorimetric measurements over a 30-min period. Then we removed the ventilated hood and started incremental human ANP infusions (Merck Bioscience AG, Cilinalf, Switzerland). We infused ANP at rates of 6.25, 12.5, and 25 ng/kg/min for 45 min each. These infusion rates have previously been shown to provide physiological to pathophysiological venous ANP concentrations in humans (6). The duration of each infusion was sufficient to attain the maximal ANP-mediated lipolytic effect of each dose (5). We repeated indirect calorimetry measurements during the last 30 min of each ANP-infusion step. When the nonselective β-adrenergic receptor blocker propranolol was applied in combination with ANP, it was given as follows: 0.2 mg/kg iv in four divided bolus doses before ANP infusion followed by continuous propranolol infusion with 0.033 mg/kg/min for 45 min each. These doses have previously been shown to inhibit isoproterenol-induced lipolysis completely (13). Venous blood and microdialysis samples were collected at baseline and every 15 min of ANP infusion.

**Instrumentation**

Before the resting phase, two venous catheters (20G; Vasocan, B. Braun, Melsungen, Germany) were placed in large antecubital veins of both arms. Infusions and blood sampling were performed on contra lateral arms. One microdialysis probe (CMA60) each was inserted into abdominal sc adipose tissue (SCAT) and into femoral skeletal muscle (quadriceps femoris, vastus lateralis) as described previously (14, 15). Respiration and electrocardiography were measured continuously (Cardioscreen; Medis GmbH, Ilmenau, Germany). Beat-by-beat finger blood pressure (Finapres; Ohmeda, Louisville, CO) was recorded continuously throughout experiments. Brachial arterial blood pressure (Dinamap; Critikon, Tampa, FL) was determined automatically every 5 min con tralaterally to the infusion side. We used a ventilated hood to monitor O₂ consumption and CO₂ production (Deltatrac II; Datex-Ohmeda, Helsinki, Finland) by indirect calorimetry to assess energy expenditure and substrate oxidation rates. Whole-body carbohydrate- and fat-oxidation rates were estimated using stoichiometric equations (16).

**Microdialysis**

Details of the microdialysis technique are described elsewhere (14, 15). Briefly, before insertion of the probes, we applied a local anesthetic (lidocaine) either as a cream for adipose tissue (EMLA; Astra GmbH, Brandenburg, Germany) or as a sc injection for muscle (Xylocitin 1%; Jenapharm GmbH, Jena, Germany). After probe insertion, we started the tissue perfusion with lactate free Ringer solution (Serumwerk Bernburg AG, Berneburg, Germany) at a flow rate of 2 μl/min. The solution was supplemented with 50 mmol/liter ethanol (B. Braun). CMA/60 microdialysis catheters and CMA/102 microdialysis pumps (both from CMA Microdialysis AB, Solna, Sweden) were used. A 60-min period was allowed for tissue recovery and baseline calibration. Two 15-min dialysate fractions were collected at baseline.

**Analytical methods**

Venous and *in vitro* glycerol concentrations were determined by an ultrasensitive radiometric method as described previously (6). Venous NEFAs were assayed with an enzymatic method (Wako kit; Unipath, West Chester, PA), and insulin concentrations were measured using a RIA (Sanofi Diagnostics Pasteur, Marnes La Coquette, France). Ethanol concentrations in perfusate (inflow) and dialysate (outflow) were measured by enzymatic techniques (17). Based on Fick’s principle, a decreased dialysate to perfusate ratio (ethanol ratio) indicates an increased blood flow and vice versa (18, 19). For simplicity, the term ethanol ratio is substituted for the term ethanol outflow to inflow ratio. Dialysate glucose, lactate, pyruvate, and glycerol concentrations were measured with a CMA/600 analyzer (CMA Microdialysis). The *in situ* recovery, assessed by near-equilibrium dialysis at a flow rate of 0.3 μl/min, was about 30% in adipose tissue and 50% in skeletal muscle for all four metabolites.

**Heart rate variability**

The electrocardiogram was analog to digital converted at 500 Hz using the Windaq Pro+ software (Dataq Instruments Inc., Akron, OH). The RR intervals (time between subsequent R waves in the electrocardiogram) were determined offline using a program written by André Diedrich (Vanderbilt University, Nashville, TN) based on PV-wave software (Visual Numerics Inc., Houston, TX). We analyzed heart rate variability in the time domain using standard techniques. In addition, we calculated spectra of RR interval time series in the high- and low-frequency range using Fast Fourier transformation-based algorithm (20).

**In vitro experiments**

Adipocytes were isolated by collagenase digestion as described previously (5). After digestion, the suspension was filtered (210 μm filter) and washed three times with PBS. Then adipocytes were brought to a suitable dilution (2000–3000 cells per 100 μl) into 10 mmol/liter Krebs Ringer bicarbonate HEPES buffer containing glucose (5.55 mmol/liter) and 20 mg/ml of BSA (pH 7.4). Then adipocytes were incubated during 90 min with increasing propranolol concentrations, namely 10⁻³, 10⁻⁴, and 10⁻⁵ mol/liter, in presence of 100 mmol/liter isoproterenol or ANP at 37 °C under gentle shaking at 120 cycles/min in a water bath. After incubation, 50 μl of medium was taken to measure glycerol, and total lipids were extracted gravimetrically as described previously (3).

**Calculations and statistics**

All data are expressed as mean ± sem. Repeated-measures ANOVA testing was used for multiple comparisons. Bonferroni’s *post hoc* test was performed, when *P* < 0.05. A value of *P* < 0.05 was considered significant.

**Results**

All subjects tolerated ANP and propranolol infusions well. Three probands had to be excluded from the analysis after experiments had been performed. One proband showed raised venous glucose concentrations at baseline on one of the study days, suggesting that he was not in the fasted state. In the second proband, NEFA measurements at baseline differed more than 2-fold on both study days. In the third subject, several venous measurements including NEFAs could not be obtained at baseline and on different time points during drug infusion. In our analysis, we included only seven subjects with a full data set.

**Hemodynamic responses**

With ANP infusions, heart rate increased dose dependently from 56 ± 1 beats per minute (bpm) at baseline to 72 ±
2 bpm at the highest ANP infusion rate ($P < 0.01$). With the combination of ANP and propranolol, heart rate was 56 ± 1 bpm at baseline and did not increase over time ($P < 0.001$ for the propranolol effect) (Fig. 1A). Heart rate variability is displayed in detail in Table 1. Heart rate variability in the time domain decreased substantially during ANP infusion. Furthermore, we observed a reduction in heart rate variability in the low-frequency and high-frequency domain with incremental ANP infusion. Propranolol attenuated ANP-induced changes in heart rate variability. However, the ANP-induced reduction in heart rate variability was not fully suppressed with propranolol. With ANP infusion, blood pressure was 118 ± 3/61 ± 3 mm Hg at baseline and 114 ± 4/59 ± 3 mm Hg at the highest ANP infusion rate (ns). With the combination of ANP and propranolol, blood pressure was 116 ± 3/68 ± 3 mm Hg at baseline and 106 ± 4/59 ± 3 mm Hg at the highest ANP infusion rate ($P = 0.06$). Mean arterial blood pressure is displayed in Fig. 1B.

**Venous measurements**

With ANP infusions, venous NEFA and glycerol concentrations increased dose dependently (Fig. 2, A and B). The response was not attenuated with propranolol. ANP increased glucose, without or with propranolol (Fig. 1C). Without propranolol, insulin was 4.2 ± 0.5 μU/ml at baseline, 4.80 ± 0.9 μU/ml at an infusion rate of 6.25 ng/kg/min, 5.3 ± 1.2 μU/ml at an infusion rate of 12.5 ng/kg/min, and 5.7 ± 0.6 at the highest ANP infusion rate ($P = 0.06$ vs. baseline).

![Fig. 1. A, Heart rate (HR) with increasing ANP dosages with and without the nonselective β-adrenergic receptor blocker propranolol. B, Mean arterial blood pressure (MAP) with ANP and with the combination of ANP and propranolol. BB, β-Adrenergic receptor blockade. ***, $P < 0.01$, ****, $P < 0.001$, compared with baseline measurement (post hoc analysis), $P < 0.001$, comparison between curves by two-way ANOVA.](https://academic.oup.com/jcem/article-abstract/91/12/5069/2656695)

**TABLE 1. Heart rate variability**

<table>
<thead>
<tr>
<th>ANP infusion rate (ng/kg/min)</th>
<th>Baseline</th>
<th>6.25</th>
<th>12.5</th>
<th>25</th>
</tr>
</thead>
<tbody>
<tr>
<td>pnn50 (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANP</td>
<td>35 ± 5</td>
<td>36 ± 5</td>
<td>22 ± 5</td>
<td>11 ± 4*</td>
</tr>
<tr>
<td>ANP and BB</td>
<td>39 ± 5</td>
<td>46 ± 5</td>
<td>38 ± 10</td>
<td>31 ± 6</td>
</tr>
<tr>
<td>hf rri (msec⁻²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANP</td>
<td>1130 ± 280</td>
<td>900 ± 160</td>
<td>810 ± 190</td>
<td>240 ± 60*</td>
</tr>
<tr>
<td>ANP and BB</td>
<td>1240 ± 270</td>
<td>1140 ± 190</td>
<td>920 ± 170</td>
<td>860 ± 220</td>
</tr>
<tr>
<td>lf rri (msec⁻²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANP</td>
<td>970 ± 250</td>
<td>1050 ± 170</td>
<td>1060 ± 170</td>
<td>490 ± 100</td>
</tr>
<tr>
<td>ANP and BB</td>
<td>1230 ± 300</td>
<td>1630 ± 360</td>
<td>1290 ± 250</td>
<td>1520 ± 390</td>
</tr>
</tbody>
</table>

pnn50, Proportion of successive normal-to-normal interval differences greater than 50 msec; hf rri, RR variability in the high-frequency range; lf rri, RR variability in the low-frequency range. BB, β-Adrenergic receptor blockade

* $P < 0.05$ ANP vs. ANP and propranolol.

With the combination of ANP and propranolol, venous insulin concentrations were 4.7 μU/ml at baseline, 4.2 ± 0.5 μU/ml at the lowest ANP-infusion rate, 4.3 ± 0.2 μU/ml at an infusion rate of 12.5 ng/kg/min, and 5.7 ± 0.6 μU/ml at the highest infusion rate (ns for propranolol effect).

**Microdialysis**

Adipose tissue ethanol ratio and glucose concentrations are given in Table 2. In abdominal SCAT, the ethanol ratio tended to decrease with and without propranolol. SCAT glucose and lactate concentrations increased without ($P < 0.05$) and with propranolol ($P < 0.01$) at the highest ANP infusion rate (Fig. 3B) (ns for propranolol effect). With ANP, the maximal increase in SCAT glycerol concentrations was 36% ($P < 0.05$) with ANP and 54% ($P < 0.01$) with the combination of ANP and propranolol at the highest ANP infusion rate (ns for propranolol effect) (Fig. 3A).

In skeletal muscle, the ethanol ratio did not change during ANP infusions with and without propranolol. Similarly, ANP did not change dialysate glucose concentrations. Yet dialysate lactate concentrations maximally increased by 25% ($P < 0.001$) with ANP and 32% ($P < 0.05$) with ANP and propranolol (Fig. 3D) (ns for propranolol effect). Dialysate pyruvate concentration increased to a maximum of 530% ($P < 0.001$) with ANP and 670% ($P < 0.001$) with ANP and propranolol ($P < 0.001$) (ns for propranolol effect). The lactate to pyruvate ratio decreased with ANP from 103 ± 43 at baseline to 24 ± 3 ($P < 0.001$) at the highest ANP infusion rate and from 354 ± 272 at baseline to 43 ± 14 ($P < 0.001$) at the highest ANP infusion rate with propranolol (ns for propranolol effect). The numerical difference in the lactate to pyruvate ratio with and without propranolol was solely explained by a single proband with an unusually low pyruvate measurement on propranolol. Skeletal muscle dialysate glycerol concentrations did not change throughout the ANP infusion (Fig. 3C).

**Indirect calorimetry**

Resting energy expenditure did not change significantly with ANP or with the combination of ANP and propranolol (Fig. 4A). The respiratory quotient tended to increase above baseline at an ANP infusion rate of 6.25 ng/kg-min but de-
creased below baseline as infusion rate was further increased (Fig. 4B). Accordingly, carbohydrate oxidation rate increased by 45% above baseline at an ANP infusion rate of 6.25 ng/kg·min and decreased by 30% below baseline at an ANP infusion rate of 25 ng/kg·min \( (P < 0.05 \text{ vs. } 6.25 \text{ ng/kg·min}) \).

Without propranolol, lipid oxidation rate tended to decrease below baseline at an ANP infusion rate of 6.25 ng/kg·min, whereas it increased to a maximum of 34% above baseline with the highest ANP infusion rate \( (P < 0.05 \text{ vs. } \text{baseline}) \).

The biphasic response of lipid oxidation rate was attenuated with propranolol. We calculated the amplitude of the change in lipid oxidation rate as the difference between maximal lipid oxidation rate and minimal lipid oxidation rate in each subject. The amplitude was \( 13 \pm 1.5 \text{ g per 6 h without propranolol and } 7 \pm 1.9 \text{ g per 6 h with propranolol} \ (P < 0.05) \).

**In vitro experiments**

Figure 5 illustrates changes in glycerol concentrations with isoproterenol and ANP in the presence and in the absence of propranolol in human mature adipocytes. Isoproterenol increased glycerol release substantially. The response was abolished with \( 1 \mu\text{mol/liter propranolol} \). Larger propranolol concentrations decreased glycerol concentrations below the baseline value. In contrast, the ANP-driven glycerol release from isolated adipocytes was not attenuated with propranolol. The relative decrease in glycerol with ANP and the highest propranolol concentration are equivalent to the decrease in glycerol values below baseline with isoproterenol and the highest propranolol concentration.

**Discussion**

We conducted in vitro and in vivo experiments to study the interaction of ANP and \( \beta \)-adrenergic receptors on human metabolism and cardiovascular regulation. The main finding of our study is that propranolol attenuated the ANP-induced changes in heart rate and heart rate variability. In contrast, ANP-induced changes in lipolysis and carbohydrate metabolism were not attenuated with propranolol. Initially, we tested the effect of isoproterenol and ANP on in vitro lipolysis, both in the presence and absence of propranolol. Adipocytes exhibited a strong lipolytic response to isoproterenol and ANP. Moderate propranolol concentrations abolished the lipolytic response to isoproterenol. In contrast, ANP-mediated lipolysis was maintained, even with high propranolol concentrations. The observation further supports the idea that \( \beta \)-adrenergic receptor agonists and ANP induce lipolysis through distinct receptor and postreceptor mechanisms \( (3, 9) \). ANP activates hormone-sensitive lipase through a cGMP-dependent pathway \( (9) \). Our results suggest that the pathway is sufficient to sustain lipolysis, even during near complete \( \beta \)-adrenergic receptor blockade. On the other hand, ANP-induced lipid oxidation tended to be responsive to \( \beta \)-adrenergic receptor blockade in this study.

Data from in vitro studies may not reflect the in vivo situation. For instance, a cell-based experiment cannot test ANP-induced changes in sympathetic activity. Sympathetic activity could be raised through baroreflex mechanisms compensating for ANP-induced vasodilatation and volume loss from the intravascular space. With higher ANP concentrations, norepinephrine concentrations increased \( (10) \). In addition, in this study, ANP infusion increased heart rate in part through \( \beta \)-adrenergic receptor stimulation. The ANP-induced reduction in heart rate variability was not fully suppressed with propranolol. The observation of decreased high frequency component during infusion suggests that ANP may also have caused a withdrawal of parasympathetic activity toward the heart in addition to the sympathetic activation.

ANP possibly increased sympathetic outflow to adipose tissue. To address this issue, we applied incremental iv ANP concentrations in humans, in both the absence and presence of near-complete systemic \( \beta \)-adrenergic receptor blockade with propranolol. Propranolol in doses applied here abolishes the lipolytic response to local isoproterenol infusion \( (13) \). Similar to earlier studies \( (6) \), ANP increased circulating NEFA and glycerol concentrations. In the present study, systemic \( \beta \)-adrenergic receptor blockade did not attenuate the response. To further address the interaction between ANP and \( \beta \)-adrenergic mechanisms on lipolysis, we assessed adipose tissue and skeletal muscle metabolism using microdialysis. We observed a tissue-specific ANP effect on lipolysis. Local concentrations of glycerol in adipose tissue increased markedly with ANP. The response was not abolished with propranolol. In contrast, ANP in skeletal muscle did not increase glycerol concentrations. Our observations, together with previous studies using local \( \beta \)-adrenergoreceptor blockade \( (5) \), indicate that ANP-induced lipolysis in humans cannot be explained by stimulation of \( \beta \)-adrenergic mechanisms.

Our findings do not completely exclude the possibility that other, nonsympathetic, mechanisms are involved in the lipolytic action of ANP. Insulin inhibits lipolysis. ANP tended to increase venous insulin concentrations without and with propranolol. ANP may reduce the hepatic deactivation of insulin, thus increasing circulating insulin concentrations \( (21) \). In addition, the increase in plasma insulin concentrations could be secondary to a net glucose release from the
liver (22). Clearly, an increase in lipolysis with ANP cannot be explained by changes in insulin concentration. Other lipolytic agents, such as ACTH, GH, and cortisol, were not altered by ANP in previous investigations (23).

NEFAs that are released through lipolysis may undergo different metabolic pathways. They may be reesterified and stored as triacylglycerides, or they may be oxidized. ANP had a biphasic effect on lipid oxidation rate with a marked increase in lipid oxidation rate at higher doses. Propranolol attenuated ANP-mediated changes in lipid oxidation rate. Thus, stimulation of β-adrenergic receptors appears to modulate ANP-induced lipid oxidation. Nonselective β-adrenergic receptor blockade impairs lipid oxidation rate during physical exercise (24). However, exercise-induced lipid oxidation during β-blockade is normalized when circulating NEFA concentrations are restored through intralipid-heparin infusion (25). Decreased NEFA availability alone cannot explain the attenuation in ANP-induced lipid oxidation during β-adrenergic receptor blockade. It is possible that β-adrenergic tone and ANP are essential cofactors converging on the same metabolic pathway. Given its important role in the regulation of substrate oxidation and its activation by adrenergic receptors (26), AMP-activated protein kinase might be involved in the metabolic interaction of the sympathetic nervous system and ANP.

Besides its effect on lipid turnover, ANP elicits complex changes in carbohydrate metabolism. Similarly to earlier reports (5, 6), venous glucose and insulin levels increased concentration dependently with ANP infusion. Reflex-mediated adrenergic receptor activation could contribute to the response. Epinephrine infusions increase blood glucose by stimulating hepatic glycogenolysis and the hepatic and renal gluconeogenesis. However, this explanation is unlikely because near-complete β-adrenergic receptor blockade did not alter the ANP-mediated increase in blood glucose concentration in our study. An alternative explanation is that ANP induced hepatic gluconeogenesis (22). Finally, increased NEFA concentrations may have led to a secondary increase in gluconeogenesis and a reduced cellular uptake of glucose (27).

Changes in circulating glucose concentration were associated with changes in glucose use at the tissue level. In
skeletal muscle and adipose tissue, ANP increases lactate production (6). Furthermore, pyruvate concentration increased in skeletal muscle. Thus, ANP stimulated glycolysis. The reduction in pyruvate to lactate ratio suggests that in skeletal muscle, a greater proportion of glucose undergoing glycolysis was fed into the Krebs cycle. No change in microdialysate glucose concentration in the setting of increased venous glucose concentration and unchanged tissue blood flow with ANP is further evidence for increased muscular glucose uptake and metabolism. These responses were not inhibited by β-adrenergic receptor blockade. However, we cannot exclude involvement of α-adrenergic mechanisms. α1-Adrenergic receptor stimulation augments glucose uptake and glycolysis in human adipose tissue (28). An alternative explanation for the increase in glucose, pyruvate, and lactate might be inhibition of pyruvate dehydrogenase activity by NEFAs (29). With an increased proportion of glucose carbon being directed into the Krebs cycle, one would expect to see an increase in systemic carbohydrate oxidation rate. We observed no change or even reduction in carbohydrate oxidation rate with ANP. It is possible that an increase in skeletal muscle glucose oxidation was masked by opposing metabolic changes in other organs, such as the liver. Indeed, in mice, ANP reduced hepatic lactate and pyruvate production due to increased gluconeogenesis (22). The liver has a greater contribution to resting energy expenditure than skeletal muscle.

The sympathetic nervous system is generally regarded as the principal regulator of human lipolysis (30). However, in vitro ANP was a more potent lipolytic agent than the β-adrenoreceptor agonist isoproterenol (2). Interestingly, ANP stimulates lipolysis in human and monkey adipocytes but not rat, mouse, rabbit, hamster, and dog adipocytes (31). The phenomenon may reflect differences in NPr expression in adipose tissue between primates and other species. The ratio of the NPrA to the NPrC, the ANP clearance receptor, is approximately 100-fold smaller in rodent compared with human adipocyte membranes (31). Clearance of natriuretic peptides by NPrC may attenuate the lipolytic effect. In obese patients, adipose tissue NPrC expression is increased, whereas natriuretic peptide concentrations are decreased (32, 33). In contrast, mice with a genetically nonfunctional NPrC are thin and lack normal fat deposits (34). Heart failure patients, in whom natriuretic peptide concentrations are elevated up to 20-fold, are prone to loss of adipose tissue, lean mass, and bone mass. The condition is called cardiac cachexia and carries a poor prognosis (35). ANP might play an important role in this setting. Insulin resistance is another common metabolic abnormality in heart failure patients (36). ANP-induced NEFA release could conceivably contribute to insulin resistance (27). Natriuretic peptide concentrations positively correlate with NEFA concentrations in patients with heart failure and coronary heart disease (37, 38). In these patients, increased NEFA concentrations are associated with increased mortality (38). Recently natriuretic peptide infu-
sions (nesiritide) have been espoused in heart failure therapy. Although improving symptoms and hemodynamic parameters, nesiritide may have a neutral or even negative effect on prognosis (39). Whether natriuretic peptide-mediated changes in lipid and/or carbohydrate metabolism are important in this regard deserves further study.

Acknowledgments

Received May 18, 2006. Accepted September 7, 2006.

Address all correspondence and requests for reprints to: Jens Jordan, M.D., Franz-Volhard Clinical Research Center, Haus 129, Charité Campus Buch, D-13125 Berlin, Germany. E-mail: jordan@fvk.charlie-buch.de.

This work was supported in part by a Deutsche Forschungsgemeinschaft grant.

Disclosure statement: The authors have nothing to disclose.

References


